1. Home
  2. CBIO vs AII Comparison

CBIO vs AII Comparison

Compare CBIO & AII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$19.26

Market Cap

537.5M

Sector

N/A

ML Signal

HOLD

Logo American Integrity Insurance Group Inc.

AII

American Integrity Insurance Group Inc.

HOLD

Current Price

$25.83

Market Cap

502.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBIO
AII
Founded
2003
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
537.5M
502.6M
IPO Year
2013
2025

Fundamental Metrics

Financial Performance
Metric
CBIO
AII
Price
$19.26
$25.83
Analyst Decision
Strong Buy
Buy
Analyst Count
6
7
Target Price
$26.67
$26.33
AVG Volume (30 Days)
242.1K
199.2K
Earning Date
04-29-2026
05-12-2026
Dividend Yield
N/A
5.27%
EPS Growth
N/A
91.53
EPS
N/A
2.76
Revenue
$18,500.00
$276,485,000.00
Revenue This Year
N/A
$35.92
Revenue Next Year
$279.20
$17.74
P/E Ratio
N/A
$9.39
Revenue Growth
N/A
35.30
52 Week Low
$8.72
$16.19
52 Week High
$27.41
$27.00

Technical Indicators

Market Signals
Indicator
CBIO
AII
Relative Strength Index (RSI) 57.80 59.42
Support Level $16.65 $25.18
Resistance Level $21.14 $27.00
Average True Range (ATR) 1.31 0.88
MACD 0.25 -0.26
Stochastic Oscillator 54.44 21.29

Price Performance

Historical Comparison
CBIO
AII

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About AII American Integrity Insurance Group Inc.

American Integrity Insurance Group Inc is engaged in the property and casualty insurance business. It provides personal residential property insurance for single-family homeowners and condominium owners as well as coverage for vacant dwellings and investment properties, predominantly in Florida. The Company's property and casualty insurance is currently offered in Florida, North Carolina, South Carolina, and Georgia.

Share on Social Networks: